{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:07:15Z","timestamp":1788448035740,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bbmt.2020.07.002","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T19:19:27Z","timestamp":1594322367000},"page":"1963-1970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant"],"prefix":"10.1016","volume":"26","author":[{"given":"Joyce J.","family":"Johnsrud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasubramanian","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Efron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice (Wes)","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.07.002_bib0001","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063","article-title":"Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study","volume":"88","author":"Boeckh","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0002","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.bbmt.2016.07.009","article-title":"Cytomegalovirus status and the outcome of T cell-replete reduced-intensity allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Verduyn Lunel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0003","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V95.7.2240","article-title":"Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation","volume":"95","author":"Broers","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0004","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V97.6.1572","article-title":"Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus leukemia effect and risk factors determining outcome","volume":"97","author":"Cornelissen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1086\/342332","article-title":"Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors","volume":"35","author":"Meijer","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0006","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1365-2141.2001.02519.x","article-title":"Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis","volume":"112","author":"Craddock","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0007","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.bmt.1705699","article-title":"Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies","volume":"40","author":"\u00d6zdemir","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0008","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3109\/10428194.2014.963079","article-title":"Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant","volume":"56","author":"Dahi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.bbmt.2009.09.019","article-title":"Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation","volume":"16","author":"Beck","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2141.2003.04264.x","article-title":"Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan","volume":"121","author":"Tomonari","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0011","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbmt.2017.09.018","article-title":"Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation","volume":"24","author":"Hammerstrom","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0012","doi-asserted-by":"crossref","first-page":"e13096","DOI":"10.1111\/tid.13096","article-title":"Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia","volume":"21","author":"Lin","year":"2019","journal-title":"Transplant Infect Dis"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0013","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0015","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1182\/blood-2006-04-020313","article-title":"Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening","volume":"108","author":"Albano","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0016","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0017","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol."},{"key":"10.1016\/j.bbmt.2020.07.002_bib0018","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/dkz499","article-title":"Clinically significant drug interaction: letermovir and voriconazole","volume":"75","author":"Duong","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0019","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.bbmt.2018.12.182","article-title":"Letermovir prophylaxis demonstrates high efficacy in adult cytomegalovirus (CMV) seropositive cord blood transplant (CBT) recipients: a comparison with pre-letermovir era CBT controls","volume":"25","author":"Lau","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0020","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0021","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.bbmt.2016.06.012","article-title":"Infection rates among acute leukemia patients receiving alternative donor hematopoietic cell transplantation","volume":"22","author":"Ballen","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clim.2008.02.008","article-title":"Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution","volume":"127","author":"Brown","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0023","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1182\/blood-2007-05-092130","article-title":"Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing","volume":"110","author":"Komanduri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0024","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El Helou","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0025","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bbmt.2010.08.010","article-title":"Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen","volume":"17","author":"Schaenman","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0026","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0730-y","article-title":"Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation","volume":"55","author":"Sharma","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0027","doi-asserted-by":"crossref","unstructured":"Anderson A, Raja M, Vazquez N, Morris M, Komanduri K, Camargo J. Clinical \u201creal-world\u201d experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients [e-pub ahead of print]. Clin Transplant. doi: 10.1111\/ctr.13866. Accessed April 30, 2020","DOI":"10.1111\/ctr.13866"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0028","doi-asserted-by":"crossref","first-page":"e13187","DOI":"10.1111\/tid.13187","article-title":"Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience","volume":"21","author":"Lin","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0029","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V99.8.3050","article-title":"Randomized study of valacylclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneice bone marrow transplants","volume":"99","author":"Ljungman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.002_bib0030","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/367836","article-title":"Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"36","author":"Winston","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:12:03Z","timestamp":1761059523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120304110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1083879120304110"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.002","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}